Clinical Trial Update: A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines [Phase 3]

View source ↗

Summary

A Phase 3 study to assess adverse events of intramuscular AGN-151586 for glabellar lines has completed, evaluating safety in adult participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Lines

Drugs mentioned

• AGN-151586

Snippet

Sponsor: AbbVie | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED